KIRSTEN MARSHALL: Open Payments
NPI 1124773650 · FULTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,478 in 161 payments from 13 companies in 2025. Trend: 2023 $2,187 · 2024 $2,228 · 2025 $2,478
Food & beverage: $2,454Education: $24
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 29 | $426 |
| Alkermes, Inc. | 37 | $348 |
| Janssen Pharmaceuticals, Inc | 13 | $306 |
| Vanda Pharmaceuticals Inc. | 11 | $259 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $240 |
| E.R. Squibb & Sons, L.L.C. | 6 | $178 |
| Otsuka America Pharmaceutical, Inc. | 11 | $156 |
| Teva Pharmaceuticals USA, Inc. | 9 | $142 |
| Axsome Therapeutics, Inc. | 5 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
Products named: INGREZZA, ARISTADA, INVEGA SUSTENNA, FANAPT, CAPLYTA, COBENFY, REXULTI, Auvelity.
Industry payments across MO — which companies pay providers there.
